Leveragen, Inc., a Boston-based biotechnology company advancing next-generation in vivo antibody discovery, announced today the issuance of a patent in Japan covering core innovations underlying its ...
Creating a clear and well-defined bioanalytical methodology to quantify humoral and cellular immune responses is critical for ...
This new article publication from Acta Pharmaceutica Sinica B, discusses how an innovative and stable mRNA-LNP microneedle vaccine elicits humoral and multifunctional cellular immune responses. During ...
Age, biological sex, and human genetic factors influence the production of antibodies during the immune response. A team of ...
An analysis of antibody responses to more than 90,000 viral protein fragments shows that age, biological sex, and genetic variation shape not only antibody levels but also the viral regions targeted, ...
Finland was the first country to offer the zoonotic avian influenza A(H5N8) vaccine manufactured by Seqirus to at-risk occupational groups following the extensive clade 2.3.4.4b A(H5N1) outbreak ...
Morning Overview on MSN
DNA origami nanoparticles show early promise for future HIV vaccines
DNA origami sounds like science fiction, but for HIV vaccine researchers it is becoming a practical design tool. By folding strands of DNA into tiny three-dimensional scaffolds, scientists can arrange ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results